M. Gion et al., Clinical evaluation of percent free prostate-specific antigen using the AxSYM system in the best analytical scenario, EUR UROL, 37(4), 2000, pp. 460-469
Objective: Percent free prostate-specific antigen (PSA) is a promising tool
for prostate cancer (CaP) diagnosis. However, its diagnostic performances
have not yet been established. The present study was carried out with the a
im of evaluating percent free PSA in the most favourable analytical conditi
ons.
Materials and Methods: Eighty-eight patients affected by newly diagnosed, u
ntreated, primary CaP, and 169 cases with biopsy-confirmed, untreated, beni
gn prostatic hypertrophy (BPH) were prospectively enrolled. Abbott AxSYM to
tal and free PSA were measured by the same technician using the same instru
ment and the same reagent batch.
Results: Percent free PSA was more effective than total PSA in differential
diagnosis between CaP and BPH in every evaluated dose range of total PSA.
In cases with total PSA >4 mu g/l, percent free PSA could have reduced by a
bout 50% the rate of unnecessary biopsies with a probably still acceptable
93% cancer detection rate. The likelihood of CaP after the determination of
percent free PSA was in fact higher than 50% using cut-off points which pr
ovide low sensitivity values (i.e. 58% in men aged 50-59 years).
Conclusions: Percent free PSA is superior to total PSA in distinguishing pr
imary CaP from BPH in patients with total PSA between 2 and 30 mu g/l and i
n reducing the rate of unnecessary biopsies in men with total PSA higher th
an 4 mu g/l. However, percent free PSA should be cautiously interpreted in
decision making in individual patients since post-test probability is relat
ively low in men aged 50-70 years. Copyright (C) 2000 S. Karger AG, Basel.